ThirtyFiveBio receives grant to continue work on GPR35 blockers

2 July 2024

Oxford, UK-based ThirtyFiveBio, a biotech company specializing in GPR35 inhibitors for gastrointestinal diseases, has announced receipt of a grant from Innovate UK.

The Biomedical Catalyst grant, amounting to $817,000, will support preclinical research to develop precision medicine approaches for GPR35 inhibitors.

Preclinical data from ThirtyFiveBio indicates that GPR35 mutations are linked to GI diseases, suggesting that blocking GPR35 may offer therapeutic benefits.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical